Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]

View source ↗

Summary

A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• CpG-STAT3 siRNA CAS3/SS3

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Status: WITHDRAWN